Novartis’ CAR-T partner in China wraps $383M take-private deal engineered by CEO
After 13 years on Nasdaq, Cellular Biomedicine Group is returning to private hands.
CEO Tony (Bizuo) Liu is a key advocate of the deal, leading …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
